Statement by Ralph G. Neas, President and CEO, GPhA, Regarding H.B. 3734 in Massachusetts

Published Online: Tuesday, June 24, 2014
PRESS RELEASE

June 24, 2014-- “GPhA applauds the Massachusetts state legislature for passing legislation allowing interchangeable biologics to be automatically substituted at the pharmacy. Laws that avoid unnecessary requirements around these new medicines not only increase patient access, but also will enable public and private payors to achieve significant savings by facilitating substitution of interchangeable biologics for more expensive versions. Massachusetts provides a compelling example of policy that embraces a practical approach.

As we get closer to the point when patients across the U.S. will be able to access these safe alternatives to costly brand name biologics, GPhA continues to support legislation that does not add burdens to current pharmacy practice and upholds the intent of the Biologics Price Competition and Innovation Act (BPCIA).”
Latest Articles
Pharmacists might be surprised to learn that Pinterest is a hotbed for anti-vaccine sentiment.
The FDA has approved betamethasone dipropionate spray, 0.05%, as a treatment for mild to moderate plaque psoriasis in patients aged 18 years and older.
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Latest Issues
$auto_registration$